Fiche publication
Date publication
octobre 2019
Journal
Scientific reports
Auteurs
Membres identifiés du Cancéropôle Est :
Dr WAGNER Alain
,
Dr EBERST Lauriane
Tous les auteurs :
Verspoor FGM, Mastboom MJL, Hannink G, Maki RG, Wagner A, Bompas E, Desai J, Italiano A, Seddon BM, van der Graaf WTA, Blay JY, Brahmi M, Eberst L, Stacchiotti S, Mir O, van de Sande MAJ, Gelderblom H, Cassier PA
Lien Pubmed
Résumé
Tenosynovial giant cell tumors (TGCT), are rare colony stimulating factor-1(CSF-1)-driven proliferative disorders affecting joints. Diffuse-type TGCT often causes significant morbidity due to local recurrences necessitating multiple surgeries. Imatinib mesylate (IM) blocks the CSF-1 receptor. This study investigated the long term effects of IM in TGCT. We conducted an international multi-institutional retrospective study to assess the activity of IM: data was collected anonymously from individual patients with locally advanced, recurrent or metastatic TGCT. Sixty-two patients from 12 institutions across Europe, Australia and the United States were identified. Four patients with metastatic TGCT progressed rapidly on IM and were excluded for further analyses. Seventeen of 58 evaluable patients achieved complete response (CR) or partial response (PR). One- and five-year progression-free survival rates were 71% and 48%, respectively. Thirty-eight (66%) patients discontinued IM after a median of 7 (range 1-80) months. Reported adverse events in 45 (78%) patients were among other edema (48%) and fatigue (50%), mostly grade 1-2 (89%). Five patients experienced grade 3-4 toxicities. This study confirms, with additional follow-up, the efficacy of IM in TGCT. In responding cases we confirmed prolonged IM activity on TGCT symptoms even after discontinuation, but with high rates of treatment interruption and additional treatments.
Mots clés
Adult, Antineoplastic Agents, therapeutic use, Australia, Disease Progression, Disease-Free Survival, Europe, Female, Giant Cell Tumor of Tendon Sheath, drug therapy, Humans, Imatinib Mesylate, therapeutic use, Middle Aged, Neoplasm Metastasis, Receptors, Colony-Stimulating Factor, antagonists & inhibitors, Retrospective Studies, Treatment Outcome, United States
Référence
Sci Rep. 2019 10 10;9(1):14551
